Co 0 2 0 2 O
- 2 3 2 3 O
morbid 3 9 3 9 O
systemic 10 18 10 18 B-chronic_disease
illnesses 19 28 19 28 I-chronic_disease
or 29 31 29 31 O
other 32 37 32 37 O
severe 38 44 38 44 O
concurrent 45 55 45 55 O
disease 56 63 56 63 O
which 64 69 64 69 O
, 69 70 69 70 O
in 71 73 71 73 O
the 74 77 74 77 O
judgment 78 86 78 86 O
of 87 89 87 89 O
the 90 93 90 93 O
investigator 94 106 94 106 O
, 106 107 106 107 O
would 108 113 108 113 O
make 114 118 114 118 O
the 119 122 119 122 O
patient 123 130 123 130 O
inappropriate 131 144 131 144 O
for 145 148 145 148 O
entry 149 154 149 154 O
into 155 159 155 159 O
this 160 164 160 164 O
study 165 170 165 170 O
or 171 173 171 173 O
interfere 174 183 174 183 O
significantly 184 197 184 197 O
with 198 202 198 202 O
the 203 206 203 206 O
proper 207 213 207 213 O
assessment 214 224 214 224 O
of 225 227 225 227 O
safety 228 234 228 234 O
and 235 238 235 238 O
toxicity 239 247 239 247 O
of 248 250 248 250 O
the 251 254 251 254 O
prescribed 255 265 255 265 O
regimens 266 274 266 274 O

Eastern 0 7 275 282 B-clinical_variable
Cooperative 8 19 283 294 I-clinical_variable
Oncology 20 28 295 303 I-clinical_variable
Group 29 34 304 309 I-clinical_variable
( 35 36 310 311 I-clinical_variable
ECOG 36 40 311 315 I-clinical_variable
) 40 41 315 316 I-clinical_variable
performance 42 53 317 328 I-clinical_variable
status 54 60 329 335 I-clinical_variable
( 61 62 336 337 O
ECOG 62 66 337 341 B-clinical_variable
performance 67 78 342 353 I-clinical_variable
status 79 85 354 360 I-clinical_variable
[ 86 87 361 362 I-clinical_variable
PS 87 89 362 364 I-clinical_variable
] 89 90 364 365 I-clinical_variable
) 90 91 365 366 O
of 92 94 367 369 O
0 95 96 370 371 B-lower_bound
, 96 97 371 372 O
1 98 99 373 374 O
or 100 102 375 377 O
2 103 104 378 379 B-upper_bound

Histologic 0 10 380 390 O
confirmation 11 23 391 403 O
of 24 26 404 406 O
ovarian 27 34 407 414 B-cancer
, 34 35 414 415 O
primary 36 43 416 423 B-cancer
peritoneal 44 54 424 434 I-cancer
or 55 57 435 437 O
fallopian 58 67 438 447 B-cancer
tube 68 72 448 452 I-cancer
cancer 73 79 453 459 I-cancer
of 80 82 460 462 O
any 83 86 463 466 O
subtype 87 94 467 474 O

Immunocompromised 0 17 475 492 O
patients 18 26 493 501 O
and 27 30 502 505 O
patients 31 39 506 514 O
known 40 45 515 520 O
to 46 48 521 523 O
be 49 51 524 526 O
human 52 57 527 532 B-chronic_disease
immunodeficiency 58 74 533 549 I-chronic_disease
virus 75 80 550 555 I-chronic_disease
( 81 82 556 557 I-chronic_disease
HIV 82 85 557 560 I-chronic_disease
) 85 86 560 561 I-chronic_disease
positive 87 95 562 570 O
and 96 99 571 574 O
currently 100 109 575 584 O
receiving 110 119 585 594 O
antiretroviral 120 134 595 609 B-treatment
therapy 135 142 610 617 I-treatment

Measurable 0 10 618 628 B-clinical_variable
disease 11 18 629 636 I-clinical_variable
or 19 21 637 639 O
non 22 25 640 643 O
- 25 26 643 644 O
measurable 26 36 644 654 O
disease 37 44 655 662 O
; 44 45 662 663 O
for 46 49 664 667 O
patients 50 58 668 676 O
with 59 63 677 681 O
non 64 67 682 685 O
- 67 68 685 686 O
measureable 68 79 686 697 O
disease 80 87 698 705 O
, 87 88 705 706 O
they 89 93 707 711 O
must 94 98 712 716 O
also 99 103 717 721 O
have 104 108 722 726 O
a 109 110 727 728 O
cancer 111 117 729 735 O
antigen 118 125 736 743 O
( 126 127 744 745 O
CA)-125 127 134 745 752 O
measurement 135 146 753 764 O
of 147 149 765 767 O
> 150 151 768 769 O
35 152 154 770 772 B-lower_bound
U 155 156 773 774 I-lower_bound
/ 156 157 774 775 I-lower_bound
mL 157 159 775 777 I-lower_bound
or 160 162 778 780 O
2 163 164 781 782 B-lower_bound
X 165 166 783 784 I-lower_bound
their 167 172 785 790 I-lower_bound
documented 173 183 791 801 I-lower_bound
nadir 184 189 802 807 I-lower_bound
on 190 192 808 810 O
2 193 194 811 812 O
separate 195 203 813 821 O
measurements 204 216 822 834 O
1 217 218 835 836 O
week 219 223 837 841 O
apart 224 229 842 847 O

Negative 0 8 848 856 B-pregnancy
urine 9 14 857 862 I-pregnancy
or 15 17 863 865 I-pregnancy
serum 18 23 866 871 I-pregnancy
pregnancy 24 33 872 881 I-pregnancy
test 34 38 882 886 O
performed 39 48 887 896 O
= 49 50 897 898 O
< 50 51 898 899 O
7 52 53 900 901 B-upper_bound
days 54 58 902 906 I-upper_bound
prior 59 64 907 912 I-upper_bound
to 65 67 913 915 O
registration 68 80 916 928 O
, 80 81 928 929 O
for 82 85 930 933 O
women 86 91 934 939 B-gender
of 92 94 940 942 O
child 95 100 943 948 O
bearing 101 108 949 956 O
potential 109 118 957 966 O
only 119 123 967 971 O

Nursing 0 7 972 979 O
women 8 13 980 985 B-gender

Other 0 5 986 991 O
active 6 12 992 998 O
malignancy 13 23 999 1009 B-cancer
= 24 25 1010 1011 O
< 25 26 1011 1012 O
3 27 28 1013 1014 B-upper_bound
years 29 34 1015 1020 I-upper_bound
prior 35 40 1021 1026 I-upper_bound
to 41 43 1027 1029 O
registration 44 56 1030 1042 O
; 56 57 1042 1043 O
EXCEPTIONS 58 68 1044 1054 O
: 68 69 1054 1055 O
non 70 73 1056 1059 B-cancer
- 73 74 1059 1060 I-cancer
melanotic 74 83 1060 1069 I-cancer
skin 84 88 1070 1074 I-cancer
cancer 89 95 1075 1081 I-cancer
or 96 98 1082 1084 O
carcinoma 99 108 1085 1094 B-cancer
- 108 109 1094 1095 I-cancer
in 109 111 1095 1097 I-cancer
- 111 112 1097 1098 I-cancer
situ 112 116 1098 1102 I-cancer
of 117 119 1103 1105 I-cancer
the 120 123 1106 1109 I-cancer
cervix 124 130 1110 1116 I-cancer

Platinum 0 8 1117 1125 B-cancer
resistant 9 18 1126 1135 I-cancer
or 19 21 1136 1138 O
refractory 22 32 1139 1149 B-cancer
ovarian 33 40 1150 1157 I-cancer
, 40 41 1157 1158 O
primary 42 49 1159 1166 B-cancer
peritoneal 50 60 1167 1177 I-cancer
or 61 63 1178 1180 O
fallopian 64 73 1181 1190 B-cancer
tube 74 78 1191 1195 I-cancer
cancer 79 85 1196 1202 I-cancer
of 86 88 1203 1205 O
any 89 92 1206 1209 O
subtype 93 100 1210 1217 O

Pregnant 0 8 1218 1226 B-pregnancy
women 9 14 1227 1232 B-gender

Prior 0 5 1233 1238 O
consent 6 13 1239 1246 O
to 14 16 1247 1249 O
have 17 21 1250 1254 O
tumors 22 28 1255 1261 B-cancer
used 29 33 1262 1266 O
for 34 37 1267 1270 O
unspecified 38 49 1271 1282 O
future 50 56 1283 1289 O
research 57 65 1290 1298 O

Prior 0 5 1299 1304 B-treatment
treatment 6 15 1305 1314 I-treatment
with 16 20 1315 1319 O
Doxil 21 26 1320 1325 B-treatment
, 26 27 1325 1326 O
topotecan 28 37 1327 1336 B-treatment
, 37 38 1336 1337 O
Gemzar 39 45 1338 1344 B-treatment
or 46 48 1345 1347 O
Taxol 49 54 1348 1353 B-treatment
chemotherapy 55 67 1354 1366 I-treatment
for 68 71 1367 1370 O
platinum 72 80 1371 1379 O
- 80 81 1379 1380 O
resistant 81 90 1380 1389 O
cancer 91 97 1390 1396 B-cancer

Receiving 0 9 1397 1406 O
any 10 13 1407 1410 O
other 14 19 1411 1416 O
investigational 20 35 1417 1432 B-treatment
agent 36 41 1433 1438 I-treatment
which 42 47 1439 1444 O
would 48 53 1445 1450 O
be 54 56 1451 1453 O
considered 57 67 1454 1464 O
as 68 70 1465 1467 O
a 71 72 1468 1469 O
treatment 73 82 1470 1479 B-treatment
for 83 86 1480 1483 O
the 87 90 1484 1487 O
primary 91 98 1488 1495 B-cancer
neoplasm 99 107 1496 1504 I-cancer

Small 0 5 1505 1510 B-treatment
molecule 6 14 1511 1519 I-treatment
kinase 15 21 1520 1526 I-treatment
inhibitors 22 32 1527 1537 I-treatment
, 32 33 1537 1538 O
such 34 38 1539 1543 O
as 39 41 1544 1546 O
pazopanib 42 51 1547 1556 B-treatment

Successful 0 10 1557 1567 O
Avatar 11 17 1568 1574 B-treatment
engraftment 18 29 1575 1586 I-treatment
with 30 34 1587 1591 O
successful 35 45 1592 1602 O
expansion 46 55 1603 1612 O
and 56 59 1613 1616 O
treatment 60 69 1617 1626 O
outcome 70 77 1627 1634 O
of 78 80 1635 1637 O
Avatar 81 87 1638 1644 B-treatment
therapy 88 95 1645 1652 I-treatment

The 0 3 1653 1656 O
following 4 13 1657 1666 O
laboratory 14 24 1667 1677 O
values 25 31 1678 1684 O
obtained 32 40 1685 1693 O
= 41 42 1694 1695 O
< 42 43 1695 1696 O
21 44 46 1697 1699 B-upper_bound
days 47 51 1700 1704 I-upper_bound
prior 52 57 1705 1710 I-upper_bound
to 58 60 1711 1713 O
registration 61 73 1714 1726 O
; 73 74 1726 1727 O
complete 75 83 1728 1736 B-clinical_variable
blood 84 89 1737 1742 I-clinical_variable
count 90 95 1743 1748 I-clinical_variable
( 96 97 1749 1750 I-clinical_variable
CBC 97 100 1750 1753 I-clinical_variable
) 100 101 1753 1754 I-clinical_variable
, 101 102 1754 1755 O
sodium 103 109 1756 1762 O
, 109 110 1762 1763 O
potassium 111 120 1764 1773 O
, 120 121 1773 1774 O
aspartate 122 131 1775 1784 O
aminotransferase 132 148 1785 1801 O
( 149 150 1802 1803 O
AST 150 153 1803 1806 O
) 153 154 1806 1807 O
, 154 155 1807 1808 O
bilirubin 156 165 1809 1818 O
and 166 169 1819 1822 O
creatinine 170 180 1823 1833 O
are 181 184 1834 1837 O
to 185 187 1838 1840 O
be 188 190 1841 1843 O
obtained 191 199 1844 1852 O
pre 200 203 1853 1856 O
- 203 204 1856 1857 O
study 204 209 1857 1862 O

Therapeutic 0 11 1863 1874 B-treatment
antibodies 12 22 1875 1885 I-treatment
, 22 23 1885 1886 O
such 24 28 1887 1891 O
as 29 31 1892 1894 O
bevacizumab 32 43 1895 1906 B-treatment

Uncontrolled 0 12 1907 1919 O
intercurrent 13 25 1920 1932 O
illness 26 33 1933 1940 O
judged 34 40 1941 1947 O
by 41 43 1948 1950 O
the 44 47 1951 1954 O
treating 48 56 1955 1963 O
investigator 57 69 1964 1976 O
to 70 72 1977 1979 O
preclude 73 81 1980 1988 O
treatment 82 91 1989 1998 B-treatment
with 92 96 1999 2003 I-treatment
chemotherapy 97 109 2004 2016 I-treatment

Vaccines 0 8 2017 2025 B-treatment
and 9 12 2026 2029 I-treatment
immunotherapy 13 26 2030 2043 I-treatment
All 27 30 2044 2047 O
of 31 33 2048 2050 O
these 34 39 2051 2056 O
exceptions 40 50 2057 2067 O
should 51 57 2068 2074 O
be 58 60 2075 2077 O
confirmed 61 70 2078 2087 O
with 71 75 2088 2092 O
the 76 79 2093 2096 O
Principal 80 89 2097 2106 O
Investigator 90 102 2107 2119 O
( 103 104 2120 2121 O
PI 104 106 2121 2123 O
) 106 107 2123 2124 O
prior 108 113 2125 2130 O
to 114 116 2131 2133 O
registration 117 129 2134 2146 O

Willing 0 7 2147 2154 O
to 8 10 2155 2157 O
agree 11 16 2158 2163 O
to 17 19 2164 2166 O
periodic 20 28 2167 2175 O
contact 29 36 2176 2183 O
with 37 41 2184 2188 O
a 42 43 2189 2190 O
member 44 50 2191 2197 O
of 51 53 2198 2200 O
the 54 57 2201 2204 O
study 58 63 2205 2210 O
team 64 68 2211 2215 O
during 69 75 2216 2222 O
the 76 79 2223 2226 O
period 80 86 2227 2233 O
that 87 91 2234 2238 O
the 92 95 2239 2242 O
cancer 96 102 2243 2249 B-cancer
has 103 106 2250 2253 O
not 107 110 2254 2257 O
recurred 111 119 2258 2266 O
and/or 120 126 2267 2273 O
has 127 130 2274 2277 O
not 131 134 2278 2281 O
become 135 141 2282 2288 O
platinum 142 150 2289 2297 O
resistant 151 160 2298 2307 O

